Jazz Pharmaceuticals plc — Director's Dealing 2024

Nov 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2024-11-08

Reporting Person: Patil Neena M (EVP & Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-08	Ordinary Shares	S	3700	$123.41	Disposed	33048	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $123.31 to $123.51. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Includes 119 ordinary shares acquired on May 31, 2024 under a Section 423 Employee Stock Purchase Plan.